ArticleLasers in surgery and medicine2026
Vaginal Laser Treatment for Genitourinary Syndrome of the Menopause: A Dose-Determining Study in Breast Cancer Survivors.
Article in Lasers in surgery and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesBreast cancer survivors (BCSs) receiving endocrine therapy frequently develop genitourinary syndrome of menopause, characterized by vaginal dryness, pain, and urinary symptoms. Fractional CO
methodsThis single-center dose-determining study was conducted at Randers Regional Hospital, Denmark. Thirty BCSs on endocrine therapy with symptomatic genitourinary syndrome of menopause underwent five monthly sessions of fractional microablative CO
resultsTwenty-seven participants (90%) completed all five sessions. Vaginal dryness decreased significantly after three treatments, with a further incremental reduction by the fifth, representing the largest session-dependent change. FSFI scores increased significantly from baseline, with additional improvements across later sessions. SCS-W and ICIQ-FLUTSsex scores decreased steadily, while UDI-6 improved from baseline but remained stable across subsequent assessments. Treatments were well tolerated, with no serious adverse events.
conclusionsFractional CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.